09.06.2020

Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris

Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.

more ...

05.06.2020

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)

more ...

15.05.2020

AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben
An der Durchführung der ca. 20.000 Testung beteiligt sich AiCuris neben den vier Chemischen und Veterinäruntersuchungsämter des Landes.

more ...

02.04.2020

AiCuris gets involved in the fight against Corona

“In times like these, biotech and pharmaceutical companies have a great societal responsibility”

more ...

12.02.2020

AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir

AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

more ...